

Retirides 0.1% Tretinoin Cream is a high-strength topical retinoid supplied in a 30g tube. Each gram of cream contains 1mg of tretinoin, equivalent to a concentration of 0.1%.
Retirides 1mg/g cream is indicated for the topical treatment of mild to moderate acne vulgaris. Tretinoin may also be prescribed off-label for selected concerns involving photoageing, fine lines, uneven pigmentation and rough skin texture.
Retirides 0.1% is authorised for the topical treatment of mild to moderate acne vulgaris. Acne develops partly through abnormal keratinisation inside the hair follicles, leading to the formation of microcomedones, blackheads, whiteheads and subsequent inflammatory lesions.
Topical tretinoin helps address this process by reducing the formation of follicular plugs and supporting the clearance of existing comedones. Retirides may be prescribed alone or as one component of a wider acne-management plan.
Tretinoin is all-trans retinoic acid, an active form of vitamin A. It interacts directly with retinoic acid receptors in the skin and influences epidermal cell development and turnover.
In acne treatment, tretinoin reduces the cohesion of cells within the follicle, helps existing comedones clear and inhibits the formation of new keratin plugs. It also increases epidermal renewal, which explains both its clinical activity and the irritation that can occur when treatment is introduced.
Retirides is labelled in Spain as Retirides 1mg/g crema. This means that every gram of cream contains 1mg of tretinoin. Expressed as a percentage, 1mg/g is 0.1%.
Retirides 1mg/g is therefore not a 1% tretinoin cream. “1mg/g” and “0.1%” are two ways of stating the same concentration.
Retirides is produced in concentrations corresponding to 0.025%, 0.05% and 0.1% tretinoin. Retirides 0.1% is the highest of these three concentrations.
A higher concentration is not automatically more suitable or more effective for an individual. The appropriate strength depends on the indication, previous tretinoin exposure, current skincare routine and ability to tolerate local irritation. Some treatment plans use a lower concentration before considering 0.1%.
Topical tretinoin also has established clinical use in the management of photoaged skin. Under medical supervision, it may be used for concerns including fine lines, rough surface texture, mottled pigmentation and uneven skin tone.
These are broader uses of topical tretinoin rather than authorised indications stated in the Retirides 1mg/g product information. Prescribing Retirides for photoageing or pigmentation is therefore considered off-label and requires an individual assessment.
Use Retirides only at the frequency specified by the prescribing clinician. The Spanish product information recommends selecting both the concentration and application frequency according to skin type, acne severity and individual response.
Applying larger quantities or using Retirides more frequently than directed will not improve the treatment result. It can cause marked redness, itching, burning and peeling.
Because 0.1% is a higher tretinoin concentration, the prescriber may recommend introducing it gradually or using it less frequently at first. The application schedule should be increased only when clinically appropriate and tolerated by the skin.
Moisturisers and cosmetic skincare can be used during treatment, but the Retirides product information advises against applying them to the skin at exactly the same time. Their placement and timing should form part of the prescribed routine.
Care is required with products that have abrasive, drying, peeling or otherwise irritating effects. These include exfoliating acids, scrubs, astringents, alcohol-based products, other retinoids and certain acne treatments. Hair-removal waxes, depilatory creams and other irritating procedures may also increase skin reactions.
An apparent increase in acne can occur during the first weeks of topical tretinoin treatment. The Retirides product information explains that this can result from accelerated clearance of microcomedones that were already developing below the visible surface of the skin.
This early change is sometimes described as “tretinoin purging”, although not everyone experiences it. Significant, painful or persistent worsening should be reviewed rather than automatically considered a normal part of treatment.
Mild irritation can accompany tretinoin use, but severe irritation is not required for the medicine to be effective. The application frequency may need to be reduced or treatment temporarily stopped if the reaction becomes persistent or pronounced.
Tretinoin does not provide an immediate change in acne, texture or pigmentation. Treatment generally requires consistent use over several weeks before progress can be assessed, with longer treatment often required for photoageing or pigmentation concerns.
The current Retirides product information does not promise a fixed results timeline. Assessment should be based on the prescribed treatment period, changes in the skin and ability to tolerate the formulation.
Local reactions reported with Retirides and topical tretinoin include:
If persistent or severe irritation develops, stop applying Retirides and obtain clinical advice. Treatment should not be applied to actively sunburned or significantly irritated skin.
Exposure to sunlight should be reduced during treatment, including on cloudy days. Avoid sunbeds and ultraviolet tanning lamps. Use suitable broad-spectrum sunscreen, protective clothing and other sun-protection measures on treated areas.
Environmental conditions such as strong wind, cold weather and low humidity can also increase dryness and irritation in tretinoin-treated skin.
Retirides requires particular assessment in people with eczema or an impaired skin barrier because tretinoin can produce pronounced irritation in eczematous skin. Its product information also lists pregnancy, planning a pregnancy, use of photosensitising medicines and a personal or family history of cutaneous epithelioma among the contraindications.
Examples of medicines that can increase photosensitivity include certain tetracyclines, fluoroquinolones, thiazides, phenothiazines and sulfonamides. All current medicines should therefore be disclosed during consultation.
The safety and efficacy of Retirides have not been established in children or in people over 50 within its authorised Spanish product information. This does not determine suitability by itself, but it requires individual clinical consideration.
Retirides must not be used during pregnancy or when planning a pregnancy. If pregnancy occurs during treatment, application should be discontinued and clinical advice obtained.
It is not known whether topical tretinoin passes into human breast milk. Use while breastfeeding requires specific clinical assessment of the potential benefit and risk.
Retirides is an oil-in-water cream rather than a gel. In addition to tretinoin, the formulation includes decyl oleate, isopropyl myristate, glyceryl monostearate, acetylated lanolin alcohol, ceteareth-30, cetyl alcohol, proline, polyethylene glycol 400 monostearate, urea, collagen, lactic acid, sodium citrate, tocopheryl acetate and purified water.
It also contains methylparaben, propylparaben and Vertalina fragrance. The fragrance contains benzyl salicylate, geraniol, amyl cinnamaldehyde, linalool and butylated hydroxytoluene. Retirides is therefore not a fragrance-free or lanolin-free tretinoin cream.
These excipients distinguish the Retirides cream vehicle from other tretinoin brands, even where the active ingredient and percentage are the same.
Retirides does not require special temperature conditions under its authorised product information. Keep the tube tightly closed, retain it in its original packaging and do not use it after the stated expiry date.
Retirides 1mg/g cream is authorised for the topical treatment of mild to moderate acne vulgaris. Tretinoin may also be prescribed off-label for selected photoageing, pigmentation and texture concerns.
Retirides is a brand of tretinoin cream. Retirides 0.1% contains tretinoin at a concentration of 1mg per gram of cream.
No. Retirides and Retin-A are separate branded tretinoin products. They can contain the same active ingredient and percentage, but their cream bases, excipients, manufacturers and product authorisations differ.
Yes. One milligram of tretinoin per gram of cream is equivalent to 0.1%. Retirides 1mg/g is not a 1% tretinoin product.
It is the highest concentration in the standard Retirides range of 0.025%, 0.05% and 0.1%. This does not mean it is the most appropriate concentration for every person or indication.
Not necessarily. A higher concentration can increase tretinoin exposure but can also increase irritation. Consistent use of a tolerated concentration may be more appropriate than using a stronger cream that repeatedly disrupts the skin barrier.
Retirides is an oil-in-water cream containing emollient and moisturising components. Gel products use a different vehicle and can have different application, absorption and tolerability characteristics. Equal percentages do not make the formulations identical.
The authorised instructions state that Retirides should not be applied until approximately 30 minutes after cleansing. Allowing the skin to dry fully can reduce the likelihood of excessive irritation.
An apparent early increase in acne can occur as developing microcomedones move towards the skin surface. Not everyone experiences this, and marked or persistent worsening should be assessed.
Topical tretinoin has clinical use in photoaged skin, including fine lines and rough texture. However, the authorised indication for Retirides 1mg/g is acne vulgaris, so its use specifically for photoageing is off-label.
Tretinoin may be incorporated into a medically supervised plan for selected forms of uneven or post-inflammatory pigmentation. It is not suitable for every pigmentation disorder, and irritation can itself worsen pigmentation in some skin types.
Yes. Retirides contains acetylated lanolin alcohol and Vertalina fragrance, including the listed fragrance allergens benzyl salicylate, geraniol, amyl cinnamaldehyde and linalool.
Retirides has historically appeared with Ferrer branding, as shown on some product packaging. The current Spanish regulatory record lists Galenicum Derma S.L.U. as the marketing-authorisation holder. Packaging can therefore vary according to the batch and period of manufacture.
Continued treatment should be reviewed periodically. The authorised product information states that the safety and efficacy of daily topical tretinoin use beyond 48 weeks have not been established for this product.
No. Retirides is a prescription-only medicine and requires consultation before it can be prescribed.
```